As reported on Healio, a novel biologic targeting two key angiogenic pathways has shown encouraging early results for the treatment of wet age-related macular degeneration
Editor’s Note: This story is a continuation of Jenny Decker’s global sailing voyage. To see the original article, please click here. Many of our Patient
AstraZeneca has received European Commission approval for Imfinzi (durvalumab) in combination with FLOT chemotherapy, a landmark achievement representing the first immunotherapy-based regimen to demonstrate survival
People with rare and chronic disease often suffer from long term pain. New ways to alleviate this pain are needed. According to a press release
“Do not go gentle into that good night. Rage, rage against the dying of the light.” –Dylan Thomas One may have thought, after six months
In a recent press release, Structure Therapeutics has reported encouraging topline results from its Phase 2 ACCESS clinical program evaluating aleniglipron, an investigational once-daily oral
As reported on Inside Precision Medicine, scientists in Germany have made an exciting discovery that could help children with a very rare and serious illness
The biotechnology sector witnessed a striking demonstration of expedited drug development this week, with Boehringer Ingelheim receiving FDA approval for an innovative lung cancer therapy
As reported by Pharma Times, Elevara Medicines has initiated a phase 2b clinical study evaluating ELV001, an investigational oral CDK4/6 inhibitor, in people with rheumatoid
Pictured above: Giuliana Noratto, Ph.D., (left) and Lauren Stranahan, Ph.D., led research showing that compounds in dark sweet cherries may help slow the growth and
Daiichi Sankyo has taken a significant step toward expanding treatment options in Japan by submitting regulatory approval for Enhertu, an advanced cancer-fighting drug designed to
As reported by FiercePharma, the U.S. Food and Drug Administration has approved the first fully independent generic version of GlaxoSmithKline’s widely used asthma inhaler, Flovent,
You can not see, hear, or touch my rare condition. I STINK! (LITERALLY) I wasn’t sure if I was going to tell my story. But
Researchers have created a fundamentally new class of HIV-fighting molecules by combining two separate antiviral mechanisms into a single engineered protein. Early laboratory results, reported
As reported on BioPharmaDive, UCB has reported positive results from a head-to-head clinical trial showing that its anti-inflammatory biologic Bimzelx was more effective than AbbVie’s
Editor’s Note: Patient Worthy is proud and honored to share Jennifer’s story with cystic fibrosis and colon cancer, originally published on the Cystic Fibrosis Research
The biotechnology sector experienced significant positive developments this week, with Xenon Pharmaceuticals’ seizure medication achieving a decisive late-stage victory while regulatory pathways accelerated for several
As reported on Healio, glucagon-like peptide-1 (GLP-1) receptor agonists, best known for treating diabetes and obesity, are emerging as unexpected players in breast cancer care.
This month, we’re taking a closer look at something that impacts millions—yet often goes unnoticed. 🌟
Inside National Kidney Month:
• Real Stories – because behind every diagnosis is a human experience that deserves to be seen and heard.
• Get Involved – because awareness only matters when it leads to action.
• Resources – because better health starts with access to the right information.
Your kidneys work for you every single day—filtering, balancing, protecting. This is your reminder to return the favor. Learn the signs. Know your numbers. Support those impacted. And take steps—small or big—toward better kidney health.
Because awareness isn’t just about knowing. It’s about doing. Share your story with us today- bit.ly/3VuxFDV
#NationalKidneyMonth #KnowYourNumbers #PreventKidneyDisease #PatientWorthy
Some conditions affect more than one part of the body, and for people living with Alport syndrome, the journey can bring many unknowns and challenges along the way. Yet behind every diagnosis is a person, a family, and a story of resilience, advocacy, and strength.
Raising awareness matters. The more people understand conditions like Alport syndrome, the more support, research, and recognition this community can receive. To everyone navigating this path—you’re not alone, and your experiences deserve to be seen and heard.
If you would like to see your rare disease featured, comment below!
#RareDiseaseOfTheWeek #RareDisease #RareDiseaseAwareness #AlportSyndrome #AlportSyndromeAwarenessMonth #PatientWorthy
March is Myeloma Action Month ❤️
Multiple myeloma is a type of blood cancer that affects plasma cells in bone marrow, disrupting the body's ability to fight infection and produce healthy blood cells.
Each year, thousands are diagnosed- rates in the US have been rising, with roughly 7-9 new cases per 100,000 people annually. The disease accounts for about 10% of all blood cancers.
Awareness matters. Early detection, recognition, research, and support can change outcomes and save lives!
#MyelomaActionMonth #PatientWorthy #whatnext
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
